Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration

A model of prostate cancer progression based on the expression pattern of informative genes in the human prostate cancer xenograft LuCaP 23.1 is presented. Apparently, there are at least 2 tumor cell populations of LuCaP 23.1, representing 2 different phenotypes. One is NSE (neuron‐specific enolase)‐positive and the other NSE‐negative. NSE‐positive tumors were recovered after hormone‐independent growth in castrated mice. These hormone‐independent tumors also expressed BCL2, a gene product shown to inhibit apoptosis. With NSE, BCL2 and PSA (prostate‐specific antigen) as identifying markers, the model specifies a putative progression sequence of the prostate cancer cell types. We also show a proposed lineage relationship among the 3 principal normal cell types found in the prostatic epithelium. © 1996 Wiley‐Liss, Inc.

[1]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[2]  R. Cohen,et al.  BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. , 1994, Archives of pathology & laboratory medicine.

[3]  A. Giallongo,et al.  Complete structure of the human gene encoding neuron-specific enolase. , 1991, Genomics.

[4]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[5]  G. Chejfec,et al.  Amphicrine cells, dysplasias, and neoplasias , 1985, Cancer.

[6]  Y. Bang,et al.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[8]  L. Donehower,et al.  Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. , 1994, Oncogene.

[9]  K Remberger,et al.  Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. , 1995, Human pathology.

[10]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Vihko,et al.  Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. , 1994, Annals of medicine.

[12]  M. Colombel,et al.  Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. , 1992, Cancer research.

[13]  A. Tischler,et al.  Multidirectional differentiation in neuroendocrine neoplasms. , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  J. Isaacs,et al.  Role of calcium in the programmed death of rat prostatic glandular cells , 1990, The Prostate.

[15]  U. Stein,et al.  The proliferative function of basal cells in the normal and hyperplastic human prostate , 1994, The Prostate.

[16]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[17]  U. Stein,et al.  Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. , 1994, Human pathology.

[18]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[19]  G Dhom,et al.  Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate , 1991, The Prostate.

[20]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .